Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics and Biogen presented 4-year Phase 1/2a open-label extension data for zorevunersen in Dravet syndrome, reporting sustained cognition/behavior improvements, durable seizure reductions, and a generally well-tolerated safety profile. Safety data showed 93% (75/81) continued into one of two OLEs, and CSF protein elevations occurred in ~94% of patients (59% treatment-emergent) with no reported hydrocephalus or associated serious/severe clinical manifestations. The pivotal Phase 3 EMPEROR study remains underway with results anticipated in Q3 2027.

Analysis

The important signal here is not the efficacy headline, it’s the durability of exposure without an accumulating tolerability problem. In CNS ASOs, the market typically discounts chronic-dosing programs heavily because small safety blemishes can become label or adoption constraints later; sustaining a long safety follow-up meaningfully improves probability-adjusted peak sales and lowers the financing overhang for STOK. For BIIB, this is still more strategic optionality than earnings relevance, so any rerating should be concentrated in STOK rather than the partner.

Second-order, a disease-modifying readthrough would pressure the current Dravet care stack more than just the named seizure therapies: rescue-med usage, inpatient utilization, and caregiver-support spend are the hidden economic pools that could get displaced if developmental outcomes truly move. That matters because the economic moat in rare epilepsy is partly operational, not just clinical; if zorevunersen shifts the standard from “control seizures” to “alter trajectory,” incumbents with symptomatic-only franchises face gradual share and pricing erosion over a 6–18 month horizon. The main counterrisk is that open-label extensions routinely overstate consistency versus randomized data.

The real catalyst path is the Phase 3 readout in 2027, so this is a sentiment and positioning trade more than a fundamental earnings trade. The stock can keep grinding on conference season, but the move is vulnerable if the presentation leans on exploratory endpoints or if the matching-adjusted comparison looks statistically fragile. The contrarian read is that the market may be underestimating the long-duration safety de-risking for STOK, while overestimating any near-term value for BIIB from a collaboration that is economically peripheral.

Key Decisions for Investors

• Long STOK as a small-cap catalyst position into/through the EEC presentations, but only on a failed initial selloff or consolidation; the risk/reward is better on weakness than chasing a gap move.
• Hedge the STOK long with a short XBI sleeve for 1-3 months to isolate idiosyncratic data risk from sector beta; thesis breaks if the stock underperforms biotech despite continued data support.
• Avoid buying BIIB on this headline alone; the collaboration is strategically useful but too small to move the core multiple, so any pop in BIIB should be sold into rather than chased.
• Watch JAZZ and other Dravet-exposed epilepsy names as a medium-term relative-value short basket if Phase 3 de-risks further; the falsifier is a clean randomized dataset that fails to convert open-label durability into differentiated control.
• Set a hard thesis check ahead of 2027 Phase 3: if randomized data do not reproduce a clinically meaningful seizure reduction plus functional benefit, re-rate STOK back to pre-approval optionality only.